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The innate inflammatory immune response must be
tightly controlled to avoid damage to the host.
Here, we showed that the tuberous sclerosis com-
plex-mammalian target of rapamycin (TSC-mTOR)
pathway regulated inflammatory responses after
bacterial stimulation in monocytes, macrophages,
and primary dendritic cells. Inhibition of mTOR by ra-
pamycin promoted production of proinflammatory
cytokines via the transcription factor NF-kB but
blocked the release of interleukin-10 via the tran-
scription factor STAT3. Conversely, deletion of
TSC2, the key negative regulator of mTOR, dimin-
ished NF-kB but enhanced STAT3 activity and
reversed this proinflammatory cytokine shift. Rapa-
mycin-hyperactivated monocytes displayed a strong
T helper 1 (Th1) cell- and Th17 cell-polarizing
potency. Inhibition of mTOR in vivo regulated the in-
flammatory response and protected genetically sus-
ceptible mice against lethal Listeria monocytogenes
infection. These data identify the TSC2-mTOR path-
way as a key regulator of innate immune homeosta-
sis with broad clinical implications for infectious
and autoimmune diseases, vaccination, cancer, and
transplantation.
INTRODUCTION
Inflammation, an essential defense mechanism, is a key event in
the response to bacterial and viral infections (Kimbrell and Beu-
tler, 2001). The coordinated secretion of pro- and anti-inflam-
matory cytokines such as IL-12 and IL-10, respectively, by
myeloid mononuclear phagocytes including monocytes, macro-
phages, and dendritic cells (DCs) is indispensable for effective
immunity (Trinchieri, 2003). Nevertheless, the cellular mecha-
nisms regulating pro- versus anti-inflammatory responses arepoorly defined. Phosphatidylinositol 3-kinase (PI3K), which is
activated early after bacterial stimulation, was elucidated as
an important molecule in innate immune cells that regulates
IL-10 and IL-12 production. Genetic or pharmacological abla-
tion of PI3K in monocytes or peripheral DCs inhibits IL-10 and
boosts IL-12 production (Fukao et al., 2002; Martin et al.,
2003). However, the molecular mechanisms that control inflam-
matory responses via PI3K signal transduction in myeloid cells
are unknown.
The tuberous sclerosis complex (TSC) protein 2 belongs to
a group of proteins linked to the PI3K pathway (Wullschleger
et al., 2006). TSC2 is a tumor suppressor that forms a heterodi-
meric complex with TSC1. Mutations in TSC1 or TSC2 give rise
to the hamartoma-syndrome tuberous sclerosis complex and
the proliferative lung disorder lymphangioleiomyomatosis
(Paul and Thiele, 2008). TSC2 is phosphorylated and inacti-
vated by the protein kinase Akt, which itself is activated by
PI3K (Inoki et al., 2002). Importantly, the TSC1-TSC2 complex
negatively regulates the mammalian target of rapamycin
(mTOR) (Inoki et al., 2002). mTOR, an essential serine-threo-
nine kinase, is a central regulator of cell growth and prolifera-
tion. mTOR directly phosphorylates the ribosomal p70S6
kinase (p70S6K) and the initiation factor 4E-binding protein 1
(4E-BP1) to initiate translation of distinct mRNAs (Hay and So-
nenberg, 2004). The prototypic mTOR inhibitor rapamycin,
a bacterial macrolide with potent immunosuppressive and an-
titumor activities, is also currently evaluated to treat tuberous
sclerosis and lymphangioleiomyomatosis (Paul and Thiele,
2008). Because of the exquisite sensitivity of T cells to the
cell-cycle-blocking effects of rapamycin, mTOR inhibition was
introduced in clinical transplantation (Huang et al., 2003). Inter-
estingly, the increased usage of rapamycin has been accom-
panied by distinct inflammatory events including lymphocytic
alveolitis, interstitial pneumonitis, and severe forms of glomer-
ulonephritis (Dittrich et al., 2004; Izzedine et al., 2005; Singer
et al., 2000; Thaunat et al., 2005). However, the underlying
mechanisms of these proinflammatory effects are largely
unknown.
Some investigators reported an anti-inflammatory property
of rapamycin on in vitro-generated DCs, whereas inImmunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc. 565
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IL-23 production (Monti et al., 2003; Taner et al., 2005; Yang
et al., 2006). Here, we investigated whether TSC and mTOR are in-
volved in the regulation of inflammatory mediators upon bacterial
stimulationof freshly isolateduntouchedmononuclearphagocytes.
We showed that activation of the mTOR pathway limits inflamma-
tory responses by blocking NF-kB and enhancing STAT3 activity.
RESULTS
Rapamycin Enhances Proinflammatory Cytokine
Production
To define a potential role of mTOR in the regulation of pro- versus
anti-inflammatory cytokines, we first assessed the effects of pro-
totypic bacterial stimuli, such as lipopolysaccharide (LPS) or
Staphylococcus aureus cells (SACs), on human peripheral blood
mononuclear cells (PBMCs) in the presence or absence of rapa-
mycin. mTOR inhibition by rapamycin in PBMCs stimulated with
LPS or SACs led to a potent upregulation of IL-12p40 production
(Figures 1A and 1B). Concurrently, the anti-inflammatory cyto-
kine IL-10 was profoundly suppressed (Figure 1A). Because
monocytes and myeloid DCs are the main producers of IL-12
in the blood (Trinchieri, 2003), we next investigated the effects
of rapamycin on freshly isolated LPS- or SAC-stimulated mono-
cytes and obtained similar results, even at low-nanomolar con-
centrations of the mTOR inhibitor (Figures 1C and 1D). Activation
of monocytes with the intracellular human pathogen Listeria
monocytogenes (L.m.), Pam3Cys, or flagellin likewise promoted
IL-12p40 and inhibited IL-10 production after rapamycin
pretreatment (Figure 1E and data not shown). Importantly,
mTOR inhibition increased the production of the biologically ac-
tive heterodimers IL-12p70 and IL-23 (Figures 1F and 1G), which
share the IL-12p40 subunit, and of the proinflammatory cyto-
kines TNF-a and IL-6 (Figures 1H and 1I and Figure S1 available
online). When freshly isolated primary myeloid DC were tested
(Figure S2), a similar increase in LPS- and SAC-mediated
IL-12p40 production and decrease in IL-10 production was ob-
served upon treatment with rapamycin (Figures 1J and 1K).
These results indicate that mTOR inhibition alters the cytokine
balance of monocytes and myeloid DC toward a proinflammatory
phenotype upon microbial stimulation.
Bacterial Stimuli Activate the mTOR Pathway
Downstream of PI3K
The ability of rapamycin to affect cytokine production suggested
an involvement of the mTOR signaling pathway in the coordi-
nated production of pro- versus anti-inflammatory cytokines.
However, the mTOR pathway has not been defined in mononu-
clear phagocytes, but it is known that bacterial stimuli activate
PI3K, which leads to phosphorylation of Akt (Arbibe et al.,
2000). In other cell types, it has been further shown that activa-
tion of Akt promotes the phosphorylation and inactivation of
TSC2 (Manning et al., 2002). We found that LPS induced Akt-de-
pendent phosphorylation of TSC2 on Ser939 in human mono-
cytes (Figure 2A). Moreover, LPS also activated the downstream
mediators of mTOR, 4E-BP1, p70S6K, and S6, whereas rapamy-
cin inhibited their phosphorylation (Figures 2A and 2B). In addi-
tion, blockade of Akt inhibited phosphorylation of 4E-BP1 and
S6, confirming that the mTOR pathway is downstream of Akt in566 Immunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc.monocytes (Figure 2C and Figure S3). Murine bone-marrow-de-
rived macrophages (BMDMs) similarly activated the mTOR path-
way after in vitro infection with live L.m. and rapamycin inhibited
this activation (Figure 2D).
Ser2448 is a well-known phosphorylation site of mTOR and
sensitive to PI3K inhibition (Sekulic et al., 2000). Ser2448 phos-
phorylation of mTOR was evident in LPS-stimulated monocytes
(Figure 2E) and could be prevented by pharmacological inhibi-
tion of PI3K with wortmannin (Figure 2E), demonstrating that
PI3K signaling is upstream of mTOR in human monocytes.
Accordingly, PI3K inhibition augmented IL-12 but suppressed
IL-10 production (Figure 2F). Taken together, these results pro-
vide evidence that the mTOR pathway is downstream of PI3K
and that this pathway can be activated by bacterial stimuli in hu-
man and murine myeloid cells.
The TSC2-mTOR Pathway Mediates the Effects of
Rapamycin on Cytokine Production
Rapamycin associates with FK506-binding protein 12 (FKBP12)
to selectively bind and inhibit a complex consisting of mTOR,
mLST8, and Raptor (mTORC1) but not a complex of mTOR,
mLST8, and Rictor (mTORC2) (Wullschleger et al., 2006).
However, prolonged treatment with rapamycin has been shown
to inhibit mTORC2 signaling in distinct cell lines (Rosner and
Hengstschlager, 2008; Sarbassov et al., 2006). Pre-exposure
of monocytes to rapamycin and subsequent washout of the
inhibitor similarly deviated cytokine production after LPS stimu-
lation indicating mTORC1-specfic effects (Figure 3A). Similar to
rapamycin, the immunosuppressive macrolide FK506 engages
FKBP12 and blocks calcineurin phosphatase instead of mTOR.
We observed that FK506 did not significantly modulate IL-12
or IL-10 production (Figure 3B) but was able to outcompete
the rapamycin effects (Figure 3C). Because rapamycin regulates
the balance of IL-12 and IL-10, hyperactivation of mTOR after
bacterial stimulation ought to reverse the pattern of cytokine pro-
duction. Accordingly, amino acids or the nucleotide ATP, which
have been shown to activate mTOR signaling (Yang and Guan,
2007), but not UTP inhibited IL-12 and simultaneously enhanced
IL-10 production (Figures 3D and 3E).
To directly address whether the mTOR pathway controls
inflammatory cytokine production, we made use of murine em-
bryonic fibroblasts (MEFs) lacking TSC2, a key negative regula-
tor of mTOR. TSC2 deficiency led to constitutive activation of the
mTOR pathway (Figure 4A). We next examined whether loss of
TSC2 might affect cytokine production in a reciprocal manner
to rapamycin. Because MEF do not produce IL-12p40, we trans-
fected MEF with an IL-12p40 promoter plasmid to assess
IL-12p40 induction. Indeed, IL-12p40 was inhibited markedly in
Tsc2/ cells and could not be induced by LPS stimulation
(Figure 4B), whereas IL-10 was increased in Tsc2/ cells
(Figure 4C). Moreover, IL-6 production was partly inhibited in
Tsc2/ cells (Figure 4D). To confirm the involvement of TSC2
also in myeloid immune cells, we employed RNA interference
in THP-1 cells to knock down TSC2 (Figure 4E). IL-12p40 and
TNF-a production was reduced in TSC2-silenced cells upon
LPS stimulation, whereas IL-10 was increased (Figures 4F, 4G,
and 4H). In addition to the data obtained with the mTOR inhibitor
rapamycin, these results demonstrate that the TSC2-mTOR
pathway critically controls inflammatory cytokine production.
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mTOR Controls Innate ImmunityFigure 1. Rapamycin Differentially Modulates Pro- and Anti-inflammatory Cytokine Production
(A and B) Human PBMC were preincubated with rapamycin or medium and then stimulated with LPS or SAC. Production of IL-12p40 and IL-10 was determined
by (A) ELISA or (B) intracellular cytokine staining. Bars represent the mean ± SEM of five donors.
(C–I) Human monocytes were pretreated with medium or rapamycin and then stimulated with medium, LPS, SAC, L.m., or LPS and IFN-g as indicated. IL-12p40
(C and E), IL-10 (D and E), IL-12p70 (F), IL-23 (G), TNF-a (H), and IL-6 (I) in the supernatants were determined by ELISA (mean ± SEM of three [C-D] or nine [H and I]
donors).
(J and K) Myeloid DCs were stimulated as indicated. IL-12p40 (J) and IL-10 (K) in the supernatants were determined by ELISA. Data are representative of three
separate experiments (mean ± SD). *p < 0.05, **p < 0.01 compared with the respective LPS or SAC controls.mTOR Negatively Regulates NF-kB Activation
We went on to elucidate the downstream signals of mTOR, which
regulate the IL-12 and IL-10 balance. IL-10 is a well-known
endogenous inhibitor of IL-12 production. However, the exoge-
nous addition of IL-10 or neutralizing anti-IL-10 did not changethe effect of rapamycin on IL-12p40 production, indicating an
IL-10-independent upregulation of IL-12p40 by mTOR inhibition
(Figure S4). Moreover, the protein-synthesis inhibitor cyclohexi-
mide did not reverse the rapamycin-induced cytokine alteration,
indicating that new protein synthesis is not required for theImmunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc. 567
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Next, we examined the activation of the kinases p38, ERK, and
JNK, which are well-known regulators of IL-12 expression
(Dong et al., 2002). Phosphorylation of p38 and ERK was not
influenced by rapamycin (Figure 2D and Figure 5A). Although ra-
Figure 2. Bacterial Stimuli Activate the
mTOR Pathway
(A–C) Human monocytes were preincubated with
rapamycin (Rap), 500 nM Akt inhibitor IV (Akt I),
or medium as indicated and stimulated with LPS.
As shown in (A) and (C), whole-cell lysates were
analyzed by immunoblotting. As shown in (B),
phosphorylation of S6 at 30 min after stimulation
was detected by immunofluorescence.
(D) BMDMs were treated as indicated and then
stimulated with 107 live L.m. Immunoblotting was
performed with the indicated antibodies.
(E) Monocytes were preincubated with 100 nM
wortmannin (WM) or medium and then stimulated
with LPS for 30 min as indicated. p-mTOR was as-
sessed by immunoblotting and intracellular stain-
ing. Total Raptor or mTOR protein served as the
control.
(F) Human monocytes were treated as indicated.
Production of IL-12p40 and IL-10 was determined
by ELISA. Data are representative of three sepa-
rate experiments (mean ± SD). *p < 0.05 compared
with the respective LPS or SAC controls.
pamycin enhanced JNK activity (Fig-
ure 5A), the main target of JNK, the tran-
scription factor complex AP-1, was not
active in monocytes, as demonstrated
by EMSA and luciferase reporter studies
(Figure 5C and Figure S6). These findings
suggest a distinct mTOR-sensitive path-
way.
The transcription factor NF-kB is a
master regulator of proinflammatory
responses and a major regulator of
IL-12p40. We observed enhanced NF-
kB activation in primary human mono-
cytes, when they were treated with rapa-
mycin and LPS compared to LPS alone,
indicating that mTOR negatively regulates
NF-kB (Figure 5B). Luciferase reporter as-
says in THP-1 and U937 cells confirmed
this hyperactivation of NF-kB, but not of
CRE or AP-1, after mTOR inhibition
(Figure 5C and Figure S7). In line with
these results, rapamycin not only en-
hanced but also prolonged IL-12p40 and
TNF-a production in monocytes for up
to 20 hr after LPS stimulation (Figure S8).
Because the mTOR pathway is consti-
tutively active in Tsc2/ cells (Figure 4A),
these cells should have a decreased
ability to activate NF-kB. Accordingly,
Tsc2/ cells displayed a significantly re-
duced LPS-inducible and basal NF-kB
activity (Figure 5D). Noticeably, rapamycin rescued NF-kB activ-
ity in LPS-triggered Tsc2/ cells to a significant extent (Fig-
ure 5D). In agreement, nuclear translocation of NF-kB was re-
duced in Tsc2/ cells (Figure 5E). Supershift assays revealed
that the composition of NF-kB family members on the NF-kB568 Immunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc.
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mTOR Controls Innate ImmunityFigure 3. mTOR Controls Pro- versus Anti-
inflammatory Cytokine Production
(A) Human monocytes were pretreated with me-
dium or rapamycin for 60 min, cells were washed
as indicated with medium and stimulated with
LPS. Production of IL-12p40 and IL-10 was
determined by ELISA and is depicted as the per-
centage ± SEM of the LPS-stimulatedcontrol (n= 3).
(B) Monocytes were treated as indicated. Produc-
tion of IL-12p40 and IL-10 was determined by
ELISA. Data are representative of three separate ex-
periments (mean ± SD).
(C) Monocytes were treated with rapamycin with or
without increasing doses of FK506 (1, 10, 100, and
5000nM) and thenstimulatedwithLPS andassayed
for IL-12p40 (n = 2).
(D and E) Human monocytes, cultured in serum-free
medium, were incubated with amino acids (aa),
ATP, or UTP and then stimulated with SAC. Cell-
free supernatants were analyzed for IL-12p40 and
IL-10 (mean ± SEM; n = 3). *p < 0.05, **p < 0.01 com-
pared with the respective LPS controls.promoter was not altered by rapamycin, and p65 was mainly oc-
cupying the NF-kB binding site (Figure S9), suggesting that
mTOR might negatively modulate p65 activity to dampen NF-
kB activation. The transactivation domain (TAD) of p65 recruits
cofactors to enhance transcription (Perkins, 2007). Moreover,
PTEN and PI3K might negatively control NF-kB activity through
p65(TAD) (Mayo et al., 2002). To test whether mTOR controls
the activity of p65(TAD), we utilized a p65(TAD)-Gal4 fusion pro-
tein in luciferase reporter assays (Rocha et al., 2003). p65(TAD)
was hyperactivated when mTOR was inhibited in human THP-
1 and murine MEF cells (Figures 5F and 5G). Moreover,
p65(TAD) activity was not induced by LPS in Tsc2/ cells,
whereas rapamycin restored LPS-dependent p65(TAD) activity
in these cells (Figure 5G).
To directly show that the enhanced NF-kB activity is responsi-
ble for the observed effects of mTOR inhibition, we blocked
NF-kB signaling with SN50, a cell-permeable peptide, which in-
hibits NF-kB translocation to the nucleus (Lin et al., 1995). SN50
abolished the rapamycin-induced augmentation of IL-12p40 and
TNF-a production in human monocytes (Figures 5H and 5I). Col-
lectively, these results demonstrate that the mTOR pathway
limits NF-kB activity in myeloid cells by modulation of the p65
transactivation domain to regulate proinflammatory cytokine
production.
mTOR Controls STAT3 Activation
Because NF-kB hyperactivation cannot explain IL-10 blockade
induced by rapamycin, we investigated the effects of rapamycin
on STAT3, given that STAT3 is a major transcription factor for
IL-10 in human monocytes (Benkhart et al., 2000; Cheng et al.,
2003) and mTOR has been implicated in the regulation of
STAT3 (Karras et al., 1997). Indeed, rapamycin inhibited tyrosine
phosphorylation of STAT3 and reduced STAT3 activity (Figure 5J
and Figure S10). Moreover, in Tsc2/ cells, STAT3 was hyper-
activated (Figure 5K). Inhibition of STAT3 via the selective inhib-itor Stattic (Schust et al., 2006) reduced IL-10 production of LPS-
treated monocytes but did not enhance production of TNF-a and
IL-12p40 (Figure 5L). In agreement, Stattic failed to upregulate
NF-kB activity in Tsc2+/+ as well as Tsc2/ cells (Figure 5M). Im-
portantly, STAT3-deficient BMDMs (Stat3Lys/) showed dimin-
ished IL-10 production compared to control cells (Stat3fl/fl) after
LPS stimulation, whereas rapamycin was still able to enhance
IL-12p40 in these cells (Figure 5N). These results demonstrate
that mTOR activates STAT3 to induce IL-10 production
and independently inhibits NF-kB to restrain proinflammatory
responses.
mTOR Transcriptionally Controls Inflammatory
Mediators and Negatively Regulates T Cell Responses
mTOR is considered to control primarily posttranscriptional
events by modulating translation and mRNA stability (Hay and
Sonenberg, 2004). However, the NF-kB hyperactivation de-
scribed above (Figure 5) strongly indicated that mTOR regulates
transcriptional processes in human monocytes. Accordingly,
increased IL-12p40 and decreased IL-10 mRNA expression
were observed in mTOR-inhibited human monocytes (Figures
6A and 6B). Rapamycin did not influence the stability of
IL-12p40 or IL-10 mRNA (Figures 6C and 6D), substantiating
the transcriptional control of IL-12p40 and IL-10 by mTOR.
To determine whether mTOR affects the transcription of other
immunomodulatory molecules in myeloid cells, we performed
microarray analysis of LPS-stimulated monocytes with or without
rapamycin. After 4 hr of LPS stimulation, 290 genes were mark-
edly modulated with rapamycin treatment (Table S1). Of these,
35 or 38 genes were more than 1.5-fold upregulated or downre-
gulated, respectively. Analysis of transcription-factor binding
sites revealed that genes containing NF-kB promoters were sub-
stantially overrepresented among the rapamycin-upregulated
genes, corroborating with the finding that mTOR controls
NF-kB activation on a genome-wide level (Figure S11).Immunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc. 569
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differentially regulated genes, we assessed protein expression
of genes that are important for the regulation of immune re-
sponses. Rapamycin prevented the upregulation of the negative
T cell regulator PD-L1 (B7-H1) and the HIV coreceptor CCR5
(Figures 6E and 6F) but superinduced the costimulatory mole-
cule CD86 on monocytes and peripheral myeloid DCs
(Figure 6G and Figure S2B). CCL22, a T cell-attracting chemo-
kine, was significantly upregulated by rapamycin, whereas the
chemokine MCP-1, which is important for neoangiogenesis
and induction of Th2 cell responses (Salcedo et al., 2000), was
downregulated (Figures 6H and 6I). Conversely, in Tsc2/ cells
MCP-1 was upregulated (Figure S12). Thus, mTOR signaling
controls the expression of a broad range of immunologically rel-
evant genes in human monocytes.
The ability of mTOR to differentially regulate distinct cytokines,
chemokines, and costimulatory molecules in myeloid cells sug-
gest an impact on subsequent T cell activation. By employing
an allogeneic T cell-activation model, we observed that rapamy-
cin pretreatment of LPS-stimulated monocytes enhanced their
T cell-stimulatory capacity (Figure 6J). Strikingly, analysis of
T cell cytokine production revealed that IFN-g and IL-17 produc-
tion was significantly higher in allogeneic T cells challenged with
mTOR-inhibited monocytes (Figures 6K and 6L). Nevertheless,
rapamycin suppressed T cell proliferation and IFN-g production
when added directly to the mixed lymphocyte culture, reflecting
its cell-cycle-blocking effect on T lymphocytes (data not shown).
These results indicate that in myeloid immune cells mTOR neg-
atively regulates the priming of Th1 and Th17 T cells.
Inhibition of mTOR Protects Mice from a Lethal Listeria
monocytogenes Infection
We found that BMDMs from BALB/c and C57BL/6 mice, similarly
to human cells, differentially regulated IL-12 and IL-10 produc-
tion upon L.m. or LPS challenge under mTOR blockade in vitro
(Figure 7A and Figure S13). To examine the physiological rele-
vance of altered cytokine production after mTOR inhibition
in vivo, we tested the effect of rapamycin on the immune re-
sponse to L.m. in infected BALB/c mice. The increased suscep-
tibility of BALB/c mice to L.m. results from an inherent inability to
express sufficient amounts of IL-12, IFN-g, and IL-6 while pro-
ducing excessive amounts of IL-10 (Dai et al., 1997; Seki et al.,
Figure 4. TSC2 Controls Pro- versus Anti-inflammatory Cytokine
Production
(A) Immunoblotting of whole-cell lysates from Tsc2+/+ and Tsc2/ MEFs was
performed with the indicated antibodies.
(B) Tsc2+/+ and Tsc2/ cells were transfected with an IL-12p40 luciferase re-
porter plasmid and then stimulated with LPS as indicated. Relative luciferase
activity per mg of protein is shown (n = 4).
(C) Tsc2+/+ and Tsc2/ cells were stimulated with LPS for 5 hr and IL-10
mRNA was determined (n = 3).
(D) Tsc2+/+ and Tsc2/ cells were stimulated with LPS for 24 hr, and produc-
tion of IL-6 in the supernatants was determined (n = 3).
(E) Immunoblot from THP-1 cells transfected with TSC2 or control siRNA and
analyzed after 96 hr.
(F–H) THP-1 cells transfected with TSC2 or control siRNA for 72 hr were left
unstimulated or were stimulated with LPS for 24 hr. Cell supernatants were an-
alyzed for (F) IL-12p40, (G) TNF-a, and (H) IL-10 (mean ± SEM; n = 3). *p < 0.05.
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cytokine imbalance in BALB/c mice is critical in controlling L.m.
infection, even in mice lacking T and B cells (Tripp et al., 1994).
Remarkably, administration of rapamycin for 3 days before re-
ceiving an LD100 or LD50 dose of L.m. significantly improved
the survival of these mice compared with that of control mice
given L.m. only (Figures 7B and 7C), even though the L.m.-spe-
cific T cell response was alleviated as expected (Figure S14). The
T cell immunosuppressant FK506 did not modulate IL-12 or IL-10
production in vitro (Figure 3B) and also did not improve survival
after L.m. infection in vivo (Figure 7B). Furthermore, depletion of
macrophages and DCs with clodronate in vivo abolished the en-
hanced rapamycin-mediated resistance after L.m. infection
(data not shown), indicating that myeloid immune cells are criti-
cal for the observed in vivo effects. Improved survival of
rapamycin-treated mice infected with L.m. was confirmed by re-
duced bacterial burdens in liver and spleen 3 days after infection
(Figure 7D). Interestingly, nitric oxide (NO), which is critical for
clearing L.m. and whose production is under the control of
NF-kB, was significantly increased in rapamycin-treated mice
(Figure 7E). In addition, rapamycin-treated mice displayed re-
ductions in the number and size of granulomatous lesions in
the liver (Figure 7F). Hence, granulocyte infiltration was reduced
to control numbers in the livers of rapamycin-treated animals
(Figure 7G).
The L.m.-resistant phenotype in rapamycin-treated mice was
accompanied by an increased production of IL-12p70 in blood
early (4 hr) after infection (Figure 7H). At later time points (48 hr),
the amount of serum IFN-g and IL-6 was also significantly
greater in rapamycin-treated animals (Figure 7H). The expres-
sion of CD68, a murine monocyte and macrophage activation
marker indicative of the production of large amounts of IL-12
(Mordue and Sibley, 2003), was examined. In rapamycin- and
control-treated mice, comparable numbers of macrophages
were present in the spleen 3 days after infection with L.m., as
shown by F4/80 staining (Figure 7I). However, a strong upregula-
tion of CD68 on splenic macrophages was observed in rapamy-
cin-treated animals (Figure 7I). Remarkably, rapamycin-treated
infected mice demonstrated deficient IL-10 production by mac-
rophages, whereas strong IL-10 expression was evident in con-
trol mice (Figure 7I). In accordance with these data, we found in-
creased production of IL-12 and decreased production of IL-10
after in vitro restimulation with LPS of rapamycin-treated and
L.m.-infected spleen cells (Figure S15). Collectively, these find-
ings further demonstrate that mTOR inhibition in vivo can skew
the pro- and anti-inflammatory cytokine response and protect
susceptible BALB/c mice from a lethal L.m. bacterial infection.
DISCUSSION
Although rapamycin was identified over 30 years ago, and inhibi-
tion of mTOR was approved as a therapeutic concept for the pre-
vention of allograft rejection in 1999 (Miller, 1999), the physiolog-
ical role of mTOR in mononuclear phagocytes remained largely
unstudied. Our results have unraveled an unanticipated role of
the mTOR signaling pathway in limiting proinflammatory cyto-
kine production induced by various bacterial stimuli. Moreover,
rapamycin treatment conveyed resistance to a lethal dose ofL.m. in susceptible mice demonstrating a direct benefit for the
host when the cytokine balance is skewed by mTOR inhibition.
The present study shows that inhibition of mTOR promotes
IL-12 and prevents IL-10 production. In this regard, activation of
PI3K signaling was demonstrated recently to be an important
negative regulatory pathway that dampens IL-12 and enhances
IL-10 production after Toll-like receptor (TLR) stimulation (Fukao
et al., 2002; Martin et al., 2003). Similarly, rapamycin promoted
IL-23 production in human macrophages stimulated with Myco-
bacterium tuberculosis (Yang et al., 2006). Recently, NF-kB was
found to be regulated by TSC2 as a survival factor to control
cell survival (Ghosh et al., 2006). We identify the mTOR pathway
as a pivotal negative regulator of NF-kB signaling but as a positive
regulator of STAT3 signaling in myeloid innate immune cells.
Activation of mTOR by inflammatory stimuli or by loss of TSC2
leads to decreased NF-kB but enhanced STAT3 activity, presum-
ably providing a feedback loop to limit excessive inflammation. In
this respect, it is interesting to note that the negative NF-kB
regulator IKK-b itself controls mTOR activity via TSC1 (Lee
et al., 2007). How does the serine-threonine kinase mTOR control
tyrosine phosphorylation of STAT3 and subsequently IL-10
production? Full activation of STAT3 occurs relatively late after
3 hr and depends on type I interferons (Chang et al., 2007; Zie-
gler-Heitbrock et al., 2003). Moreover, in murine macrophages,
LPS-induced IL-10 production is completely dependent on the
type I interferon receptor (IFNAR) (Chang et al., 2007). Because
the mTOR pathway has been recently implicated to regulate
type I interferon production (Colina et al., 2008), a sequential
activation loop is conceivable, in which mTOR stimulates type I
interferon, which subsequently activates STAT3 and IL-10 via
IFNAR. These results provide a framework to study the complex
regulatory networks that control the activation of NF-kB and
STAT3 as well as the balance of IL-12 and IL-10 in innate phago-
cytic cells.
Currently, rapamycin is used as an alternative immunosup-
pressive treatment to calcineurin inhibitors to avoid or ameliorate
chronic allograft damage (Halloran, 2004). However, distinct
proinflammatory side effects have been recognized with the
increased use of rapamycin, including lymphocytic alveolitis, in-
terstitial pneumonitis, anemia associated with chronic inflamma-
tion, and severe forms of glomerulonephritis (Dittrich et al., 2004;
Izzedine et al., 2005; Singer et al., 2000; Thaunat et al., 2005).
The present findings may provide a basis for a better under-
standing of these peculiar inflammatory conditions that exist de-
spite the potent immunosuppressive effects of mTOR inhibitors.
Recently, mTOR inhibitors have shown promising results in
advanced clinical trials against certain malignancies including
renal cell carcinoma, mantle cell lymphoma, and endometrial
cancers (Faivre et al., 2006). Upon mTOR inhibition, we observed
an altered cytokine milieu characterized by increased production
of the antitumor cytokine IL-12 and IL-10 ablation, which is con-
sidered to foster escape from immunosurveillance. These results
may add another dimension to explain the antitumor potency of
mTOR inhibitors. Because the anticancer effects of mTOR inhib-
itors are attributed partially to their ability to prevent angiogene-
sis (Guba et al., 2002), it is interesting to note that rapamycin ef-
ficiently inhibited MCP-1, a chemokine that is produced by
tumor-associated macrophages and that has been shown to
promote neoangiogenesis (Salcedo et al., 2000).Immunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc. 571
Immunity
mTOR Controls Innate Immunity572 Immunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc.
Immunity
mTOR Controls Innate ImmunityInsummary,wehave identifiedand characterizeda critical func-
tion of TSC2 and mTOR in regulation of the quality and quantity of
the inflammatory reaction invitro and invivo. Activation of mTOR in
mononuclear phagocytic cells enhances STAT3 activity and IL-10
but reduces proinflammatory molecules and NF-kB activation,
whereas inhibition of mTOR with rapamycin has reciprocal effects.
Thesefindings suggest new therapeutic avenues for the regulation
of pro- versus anti-inflammatory mediators, with potential rele-
vance to cancer therapy, the design of novel adjuvants, and the
control of distinct infectious and autoimmune diseases.
EXPERIMENTAL PROCEDURES
Reagents
LPS from E. coli 0111:B4, wortmannin, ATP, and UTP were from Sigma. SAC
(PANSORBIN), SN50, Akt inhibitor I and IV, Stattic, and FK506 were from Cal-
biochem. Rapamycin was from Calbiochem, Sigma, LKT, or Wyeth Pharma-
ceuticals.
Cell Culture
Human peripheral blood mononuclear cells (PBMCs) were isolated as de-
scribed (Saemann et al., 2005). Monocytes were isolated from PBMCs by
MACS with CD14 Microbeads (Miltenyi Biotec). Myeloid DCs were isolated
with the BDCA-1 dendritic cell Isolation kit (Miltenyi Biotec). RPMI 1640 supple-
mented with 2 mM L-glutamine, 100 mg/ml streptomycin, 100 U/ml penicillin,
and 10% FCS (Hyclone) was used as culture medium. We additionally added
50 mM b-mercaptoethanol and 1 mM sodium pyruvate for THP-1 cells. THP-1
cells were pretreated with 1.2% DMSO for 24 hr before stimulation. Mouse em-
bryonic fibroblasts (MEFs) were cultured in DMEM containing 4.5 g/L glucose,
2 mM L-glutamine, 100 mg/ml streptomycin, 100 U/ml penicillin, and 10% FCS.
Tsc2+/+ p53/ and Tsc2/ p53/ MEFs were a kind gift of D. Kwiatkowski.
Stat3flox/flox mice, backcrossed to C57BL/6, were cross-bred with B6.129P2-
Lyz2tm1(cre)Ifo/J (The Jackson Laboratory) for generating Stat3Lys/ and
Stat3fl/fl (littermate controls) mice. BALB/c and C57BL/6 mice were purchased
from Harlan Winkelmann. BMDMs from were isolated and grown as described
(Strobl et al., 2005) and were washed 1 day before stimulation.
Measurement of Cytokine Production
We pretreated 13 106 cells for 90 min with the indicated concentrations of ra-
pamycin, wortmannin, stattic, 10nM FK506, or 18 mM SN50 and then stimu-
lated them with 100 ng/ml LPS (±30 ng/ml IFN-g as indicated), 75 mg/ml
SAC, or 107 L.m. in 24-well plates. Cell-free supernatants were collected after
20–24 hr. In some experiments, human monocytes were cultured in macro-
phage-SFM medium (Invitrogen), incubated with 1% amino acids, 10 mM
ATP, or 10 mM UTP overnight, and stimulated with 20 mg/ml SAC. Cytokineswere measured by ELISA to IL-12p40, IL-12p70, IL-10, TNF-a, IL-6, IL-17,
IFN-g (all R&D Systems), and IL-23 as well as MCP-1 (Bender MedSystems).
Murine cytokines were determined by the Luminex bead system with beads
from Upstate and read on a Luminex 100 reader.
Analysis of Signal Transduction Events
A total of 13 107 monocytes, 13 107 BMDM, or 70% confluent MEFs starved
overnight were treated and stimulated as indicated. Extract preparation and
western blotting was done as described (Saemann et al., 2005). Antibodies
were p-mTOR (Ser2448), p-p70S6K (Thr389), p70S6K, p-4E-BP1 (Thr37/46),
4E-BP1, p-TSC2 (Ser939), Raptor, p-p38 (Thr180/Tyr182), p-S6 (Ser 240/
244), p-STAT3 (Tyr705), STAT3 (all Cell Signaling Technology), p-Erk
(Tyr204), and p38 (Santa Cruz Biotechnology). For detection of p-mTOR by
FACS, monocytes were fixed with 2% formaldehyde, permeabilized with
0.1% saponin, and stained with p-mTOR and Alexa-Fluor-448-labeled goat
anti-rabbit IgG (Molecular Probes). JNK activity was determined with the
SAPK/JNK Kinase Assay Kit (Cell Signal Technology).
Immunoflourescence Microscopy
Cells were applied to poly-L-lysine-coated slides (Marienfeld), fixed with 4%
paraformaldehyde, quenched with 100 mM glycine cells, permeabilized with
methanol, blocked with 1% BSA, and stained with p-S6 antibody or isotype con-
trol overnight at 4C. Cells were stained with Alexa-Fluor-448-labeled goat anti-
rabbit IgG (Invitrogen), underwent nuclear tracking with 0.5 mg/ml Hoechst-
33342 (Invitrogen), and were mounted in Vectashield mounting medium.
RNAi
THP-1 cells were transfected in full medium without antibiotics with 100 nM ON-
TARGETplus SMARTpool human TSC2 or 100 nM ON-TARGETplus siCON-
TROL nontargeting pool (Dharmacon) with Lipofectamine RNAiMAX (Invitrogen)
in accordance with the manufacturer’s protocol. Cells were used after 72 hr.
Electrophoretic Mobility-Shift Assay
Electrophoretic mobility-shift assay was performed as described (Saemann
et al., 2005). Oligonucleotides resembling the consensus binding site for NF-
kB, STAT3, and AP-1 as well as antibodies for supershift assays were from
Santa Cruz Biotechnology.
Reporter-Gene Assays
Reporter constructs for NF-kB, AP-1, and CRE were from Stratagene.
p65(TAD) and Gal4-Luc plasmids were a kind gift of N. Perkins. A renilla lucif-
erase construct was cotransfected for expression normalization. THP-1 cells
were transfected with Lipofectamine LTX and Plus Reagent for 24 hr. MEFs
were transfected with Lipofectamine for 3–5 hr. Cells were treated and stimu-
lated for 20 hr. Lysates were prepared with passive lysis buffer (Promega) and
assayed for luciferase activity.Figure 5. The mTOR Pathway Regulates NF-kB and STAT3
(A) Human monocytes were preincubated with rapamycin or medium and then stimulated with LPS for the indicated time points. Cell lysates were analyzed by
immunoblotting or for JNK activity.
(B) DNA-binding activity of NF-kB in nuclear extracts from monocytes, which were stimulated for 4 hr, was analyzed by EMSA.
(C) THP-1 cells were transfected with NF-kB, CRE, or AP-1 luciferase reporter plasmids and treated as indicated. Luciferase activity is shown as the mean ± SEM
of three independent experiments performed in triplicate.
(D) Tsc2+/+ and Tsc2/ cells were transfected with an NF-kB reporter plasmid and stimulated as indicated. Luciferase activity is shown as the mean ± SEM of
three independent experiments performed in triplicate.
(E) NF-kB DNA-binding activity in nuclear extracts from Tsc2+/+ and Tsc2/ cells, which were stimulated for 2 hr with LPS, was analyzed by EMSA.
(F and G) THP-1 (F) or Tsc2+/+ and Tsc2/ (G) cells were transfected with a Gal4 luciferase reporter and an expression plasmid encoding a p65(TAD)-Gal4 fusion.
Luciferase activity is shown as the mean ± SEM of three independent experiments performed in triplicate.
(H and I) Human monocytes were treated with medium, the NF-kB inhibitor SN50, or rapamycin as indicated and stimulated with LPS. The concentration of IL-12p40
(H) and TNF-a (I) in the supernatant was determined by ELISA. Bars represent percentage ± SEM of the LPS-stimulated control performed in duplicate (n = 3).
*p < 0.05, **p < 0.01 compared with the respective LPS controls, or as indicated. n.s., not significant.
(J) Human monocytes were treated as indicated. Cell lysates were analyzed for STAT3 phosphorylation.
(K) Immunoblotting of cell lysates from Tsc2+/+ and Tsc2/ MEFs was performed with the indicated antibodies.
(L) Monocytes were treated with the indicated amounts of Stattic and then stimulated with LPS (n = 3).
(M) Tsc2+/+ and Tsc2/ cells were transfected with an NF-kB reporter plasmid and stimulated as indicated (n = 2).
(N) Stat3Lys/ and Stat3fl/fl BMDM were stimulated with rapamycin and/or LPS as indicated for 4 hr. IL-10 and IL-12p40 mRNA levels were assessed by RT-PCR
(n = 3).Immunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc. 573
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Cells were incubated with antibodies (see figure legends) and analyzed on
a FACSCalibur. Anti-PD-L1 was kindly provided by O. Majdic.
T Cell Stimulation
Allogeneic T cell activation was performed as described (Saemann et al., 2005).
Quantitative RT-PCR
RNA from 23 106 monocytes or 70% confluent MEFs was extracted in TRIzol
(Invitrogen). cDNA was generated by Superscript II (Invitrogen). mRNA levels
were determined by TaqMan Gene Expression Assays (Applied Biosystems)
on a ABI Prism 7000 and normalized to 18S rRNA. For measurement of
mRNA stability, 10 mg/ml actinomycin D was added to the medium- or rapamy-
cin-pretreated monocytes 3 hr after stimulation with LPS and RNA was ex-
tracted at the indicated time points.
Microarrays and Data Analysis
A total of 107 CD14+ monocytes from four different donors were stimulated for
4 hr. Cells were frozen at 80C. Sample preparation and hybridization to a
PIQOR Immunology Microarray Human Antisense was performed at the Milte-
nyi Microarray Service Unit.
Figure 6. Modulation of Inflammatory Medi-
ators at the Transcriptional Level by Rapa-
mycin in Human Monocytes and the Impact
on T Cell Activation
(A and B) Kinetics of (A) IL-12p40 and (B) IL-10
mRNA in monocytes were assessed by RT-PCR.
mRNA levels are depicted as percentage of the
4 hr LPS-stimulated samples (mean ± SEM; n = 4).
(C and D) Monocytes were pretreated with rapa-
mycin or medium and then stimulated with LPS
for 2 hr. Subsequently, actinomycin D was added,
and degradation of (C) IL-12p40 and (D) IL-10 was
monitored by real-time PCR. Results depict one
representative example ± SEM of four donors.
(E–G) Monocytes were pretreated with rapamycin
and stimulated with LPS for 48 hr. PD-L1 (E),
CCR5 (F), and CD86 (G) surface expression was
analyzed by flow cytometry. Results are represen-
tative of four independent (E and F) or represent
the mean of five separate experiments (G).
(H and I) Monocytes were treated as indicated.
Production of (H) CCL22 and (I) MCP-1 was deter-
mined by ELISA (n = 4).
(J–L) Monocytes were pretreated with rapamycin
or medium and stimulated with LPS for 24 hr. Cells
were cocultured with allogeneic T cells at the indi-
cated ratios.
(J) Proliferation was measured on day 6 and is ex-
pressed as the mean of triplicate cultures. One
representative experiment of four is shown.
(K and L) Monocytes were treated as described,
washed, and added to allogeneic T cells at a ratio of
1:4. IFN-g and IL-17 in the cultures was
determined on day 2 and 6, respectively (mean
± SEM; n = 3). *p < 0.05, **p < 0.01 compared
with the respective LPS controls.
Listeria monocytogenes Infection Model
Female BALB/c mice (7–8 weeks) were injected
i.p. with 1.5 mg/kg/day rapamycin. Rapamycin
was suspended at 1 mg/ml in sterilized medium
(1 g sodium carboxymethylcellulose (Sigma-Al-
drich) and 1.25 g Tween 80 (Sigma) per 500 ml deionized water) with an ultra-
sound bath. The stock solution was diluted to 300 mg/ml with PBS for injection.
L.m. serovar 1/2 A was cultured in brain-heart infusion broth. For the survival
model, daily treatment of BALB/c mice with rapamycin or medium alone
started 3 days before logarithmically dividing L.m. were injected i.p. and con-
tinued until the end of the experiment. Rapamycin did not affect growth of L.m.
(data not shown). All studies were approved by the official Austrian ethics
committee for animal experiments (GZ.68.205/67-BRGT/2003; GZ.68.205/
171-BrGT/2005).
Determination of Bacterial Load, Nitric Oxide Production, and
Granulocyte Infiltration
We determined viable bacteria in liver homogenates by plating serial dilutions
on Oxford Listeria selective agar plates (Merck). Serum nitrate and nitrite levels
were determined with the Griess reagent (Strobl et al., 2005). Myeloperoxidase
activity in liver homogenates was monitored at 560 nm.
Histology and Immunohistochemistry
Liver and spleen of mice were removed on day 3, fixed in 4.5% phosphate-
buffered formaldehyde, and embedded in paraffin. Sections were cut and
stained with hematoxylin and eosin (H&E) (1003 magnification). For immu-
nohistochemical detection of proteins (2003 magnification), rat anti-mouse574 Immunity 29, 565–577, October 17, 2008 ª2008 Elsevier Inc.
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mTOR Controls Innate ImmunityF4/80 and CD68 (Serotec) and goat anti-rat IL-10 (R&D Systems) were used. A
biotin-streptavidin-horseradish peroxidase-based method was used for de-
tection of the primary antibodies.
Figure 7. Rapamycin Protects Mice from
Listeria monocytogenes Infection andMod-
ulates Innate Immunity
(A) BMDMs from BALB/c mice were treated with
10, 100, or 500 nM rapamycin (Rap) and L.m. as in-
dicated. IL-12p40 and IL-10 in the supernatants
were determined by ELISA.
(B and C) BALB/c mice were pretreated i.p. with
rapamycin, FK506, or medium for 3 days as
indicated and then challenged with (B) 107 L.m.
(n = 6) or (C) 106 L.m. (n = 12). Survival was moni-
tored for 8 days. Statistics are indicated as p
values in the figures. One representative experi-
ment of two independent experiments is shown.
(D) BALB/c mice were pretreated as above and
challenged with 105 L.m. On day 3, the numbers
of bacteria in the spleen and liver were determined
(n = 3).
(E–H) BALB/c mice were pretreated as above and
challenged with 104 L.m. As shown in (E), on day 3,
we assessed plasma levels of nitrate (NO3
) and
nitrite (NO2
) as a marker of nitric oxide production
(n = 8-9). As shown in (F), on day 3, liver histomor-
phology was analyzed by H&E staining. Granulo-
matous lesions are indicated (by arrows). (G)
shows relative myeloperoxidase (MPO) activity in
the livers of control and infected mice with or with-
out rapamycin. As shown in (H), serum concentra-
tions of IL-12p70, IFN-g, and IL-6 were deter-
mined from infected animals 4 and 48 hr
postinfection (mean ± SEM; n = 3).
(I) Spleens were analyzed by immunohistochemi-
cal staining of F4/80, CD68, and IL-10 on day
3 postinfection. *p < 0.05 compared with the
respective L.m. controls.
Statistics
Cytokine levels were compared with Student’s t
test. Survival data shown as Kaplan Meier plots
were analyzed with the log-rank test for the com-
parison of the groups.
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